Sign In
Buy AMSF
AMERISAFE Earnings Calls
| Release date | Oct 29, 2025 |
| EPS estimate | $0.550 |
| EPS actual | $0.550 |
| Revenue estimate | 80.306M |
| Revenue actual | 81.984M |
| Revenue Surprise | 2.09% |
| Release date | Jul 24, 2025 |
| EPS estimate | $0.550 |
| EPS actual | $0.530 |
| EPS Surprise | -3.64% |
| Revenue estimate | 78.102M |
| Revenue actual | 81.088M |
| Revenue Surprise | 3.82% |
| Release date | Apr 29, 2025 |
| EPS estimate | $0.590 |
| EPS actual | $0.600 |
| EPS Surprise | 1.69% |
| Revenue estimate | 76.781M |
| Revenue actual | 72.597M |
| Revenue Surprise | -5.45% |
| Release date | Feb 26, 2025 |
| EPS estimate | $0.600 |
| EPS actual | $0.670 |
| EPS Surprise | 11.67% |
| Revenue estimate | 77.366M |
| Revenue actual | 74.049M |
| Revenue Surprise | -4.29% |
Last 4 Quarters for AMERISAFE
Below you can see how AMSF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 26, 2025 |
| Price on release | $50.83 |
| EPS estimate | $0.600 |
| EPS actual | $0.670 |
| EPS surprise | 11.67% |
| Date | Price |
|---|---|
| Feb 20, 2025 | $49.42 |
| Feb 21, 2025 | $49.47 |
| Feb 24, 2025 | $49.97 |
| Feb 25, 2025 | $51.50 |
| Feb 26, 2025 | $50.83 |
| Feb 27, 2025 | $50.80 |
| Feb 28, 2025 | $51.46 |
| Mar 03, 2025 | $52.16 |
| Mar 04, 2025 | $50.95 |
| 4 days before | 2.85% |
| 4 days after | 0.236% |
| On release day | -0.0590% |
| Change in period | 3.10% |
| Release date | Apr 29, 2025 |
| Price on release | $49.84 |
| EPS estimate | $0.590 |
| EPS actual | $0.600 |
| EPS surprise | 1.69% |
| Date | Price |
|---|---|
| Apr 23, 2025 | $49.25 |
| Apr 24, 2025 | $49.63 |
| Apr 25, 2025 | $48.89 |
| Apr 28, 2025 | $49.02 |
| Apr 29, 2025 | $49.84 |
| Apr 30, 2025 | $46.49 |
| May 01, 2025 | $45.83 |
| May 02, 2025 | $46.64 |
| May 05, 2025 | $46.53 |
| 4 days before | 1.20% |
| 4 days after | -6.64% |
| On release day | -6.72% |
| Change in period | -5.52% |
| Release date | Jul 24, 2025 |
| Price on release | $43.58 |
| EPS estimate | $0.550 |
| EPS actual | $0.530 |
| EPS surprise | -3.64% |
| Date | Price |
|---|---|
| Jul 18, 2025 | $45.18 |
| Jul 21, 2025 | $44.09 |
| Jul 22, 2025 | $44.11 |
| Jul 23, 2025 | $44.00 |
| Jul 24, 2025 | $43.58 |
| Jul 25, 2025 | $46.23 |
| Jul 28, 2025 | $46.47 |
| Jul 29, 2025 | $45.98 |
| Jul 30, 2025 | $45.13 |
| 4 days before | -3.54% |
| 4 days after | 3.56% |
| On release day | 6.08% |
| Change in period | -0.111% |
| Release date | Oct 29, 2025 |
| Price on release | $39.73 |
| EPS estimate | $0.550 |
| EPS actual | $0.550 |
| Date | Price |
|---|---|
| Oct 23, 2025 | $41.91 |
| Oct 24, 2025 | $41.45 |
| Oct 27, 2025 | $41.19 |
| Oct 28, 2025 | $40.60 |
| Oct 29, 2025 | $39.73 |
| Oct 30, 2025 | $39.94 |
| Oct 31, 2025 | $40.08 |
| Nov 03, 2025 | $39.81 |
| Nov 04, 2025 | $40.14 |
| 4 days before | -5.20% |
| 4 days after | 1.03% |
| On release day | 0.529% |
| Change in period | -4.22% |
AMERISAFE Earnings Call Transcript Summary of Q3 2025
AMERISAFE reported solid Q3 2025 operating results driven by disciplined underwriting and broad-based growth. Key financials: gross written premiums rose 7.2% year-over-year to $80.3M (voluntary premiums +10.6%), net income was $13.8M ($0.72/share) and operating net income was $10.6M ($0.55/share). The company delivered a 20.5% return on average equity and a 90.6% combined ratio for the quarter, with an accident-year loss ratio around 71% and $8.9M of favorable prior-year reserve development. Policy count and insured payrolls increased (policy count +~11% YoY; quarter-over-quarter +2.7%), renewal retention remained strong at 93.6%, and frequency of claims remains historically low despite some severity pressure. Capital actions: Board declared regular quarterly dividend $0.39 and a $1.00 special dividend (payable Dec 12, 2025); the company repurchased ~31,000 shares in the quarter and continues a balanced capital deployment approach. Investment portfolio is high-quality (AA- average), $817M in investments/cash at quarter-end, portfolio tax-equivalent book yield ~3.9% with new purchases yielding ~77 bps over roll-off. Book value per share rose to $14.47 (YTD +7.1%); statutory surplus strengthened to $259M. Management reiterated focus on profitable, durable organic growth, conservative capital management, and continued investment in people and technology.
